Amino Acid Metabolism and Endocrine Therapy Resistance
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Molecular Mechanism of Resistance
SLC7A5 (solute carrier amino acid transporter 7a5) protein expression regulates leucine amino acid uptake and represents a key molecular determinant of breast cancer cell resistance to tamoxifen endocrine therapy.
Therapeutic Implications
Understanding SLC7A5-mediated resistance mechanisms may facilitate development of combination approaches to overcome endocrine therapy resistance in ER-positive breast cancer.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.